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We	report	20	cases	of	extensively	drug-resistant	tuberculo-
sis	managed	 in	France.	Treatment	was	 individualized	and	
included bedaquiline and linezolid for most patients and sur-
gery	in	8	patients.	At	last	follow-up	(22	months),	19	patients	
had achieved conversion from positive to negative on culture 
testing.	These	promising	results	of	comprehensive	manage-
ment	obtained	in	a	small	series	deserve	confirmation.
Multidrug-resistant tuberculosis (TB) and extensively drug-resistant TB (XDR TB) are among the most 
difficult infections to treat and are major public health con-
cerns worldwide (1). In France, the number of imported 
XDR TB cases has dramatically increase recently, espe-
cially cases originating from countries of the former Union 
of Soviet Socialist Republics (2).
The Study
During 2009–2014, we identified 20 persons who were 
admitted to 2 tertiary-care hospitals in Rennes and Paris, 
France, with culture-positive XDR TB infections. Patients 
were identified through hospital database searches; patient 
data were extracted from medical charts. For each patient, 
we performed direct examination of sputum smears; cul-
tures on Lowenstein-Jensen medium; genotypic resistance 
profiling (GenoType MTBDR Plus; HAIN Lifescience, 
Nehren, Germany); and in vitro drug susceptibility testing 
(DST) on Lowenstein-Jensen medium, according to the 
proportions method.
All patients were isolated in negative-pressure rooms 
until their respiratory sample culture results converted from 
positive to negative (hereafter referred to as culture con-
version). Medical and surgical therapeutic options were 
determined during multidisciplinary meetings involving 
infectious diseases, respiratory diseases, microbiology, and 
thoracic surgery departments. In agreement with World 
Health Organization guidelines (3), we selected anti-TB 
drug therapy on the basis of results from previously used 
agents or genotypic and phenotypic DST. Throughout hos-
pitalization, treatment toxicity was carefully monitored 
through clinical assessments, routine laboratory tests, 
therapeutic drug monitoring, audiograms for patients on 
aminoglycosides, and weekly electrocardiograms. Treat-
ment efficacy was monitored through thoracic imaging and 
monthly examination of respiratory samples. For patients 
with nondisseminated pulmonary TB, surgery was consid-
ered at the initiation of medical treatment if success of the 
treatment was deemed unlikely because of extensive le-
sions or after 3 months of optimized medical treatment if 
sputum conversion was not achieved. In agreement with 
procedures implemented by the French Information Protec-
tion Commission, all data were anonymized and collected 
on a standardized form.
The 20 XDR TB patients (Table 1) had recently ar-
rived in France from Georgia (n = 17), Armenia (n = 2), 
and the Russian Federation (n = 1); median duration be-
tween arrival and hospitalization was 2 (interquartile range 
[IQR] 1–7) days. Median delay from admission to initiation 
of any anti-TB treatment was 18 (IQR 11–25) days.
During the intensive phase of treatment, each patient 
was given 4–9 presumably active anti-TB agents (Table 
2). All patients required long-term central venous access 
for administration of amikacin or carbapenems. Duration 
of medical treatment was individualized but continued a 
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minimum of 12 months after culture conversion. Median 
duration of treatment was 24 (range 18–51) months. Me-
dian length of stay in the acute-care setting was 67 (IQR 
55–124) days.
The following grade 3 or 4 treatment-associated ad-
verse events (Common Terminology Criteria for Ad-
verse Events, http://evs.nci.nih.gov/ftp1/CTCAE/CT-
CAE_4.03_2010-06-14_QuickReference_5x7.pdf) were 
reported in 18 patients: digestive side effects (14 patients), 
hepatitis (1 patient), peripheral neuropathy (7 patients), 
neuropsychiatric side effects (3 patients), and hearing im-
pairment (3 patients). Candidemia developed in 5 patients. 
No grade 3 or 4 nephrotoxicity or cytopenia or significant 
QT interval prolongation were reported. Adverse events re-
lated to anti-TB agents were managed by a wide range of 
symptom treatments.
Thoracic surgery was performed in 8 patients (lobec-
tomy in 5, pneumonectomy in 3), of whom 2 had severe 
postsurgical complications. Six of these patients were cul-
ture-positive before surgery, and their cultures converted a 
median of 25 days postsurgery (IQR 20–33 days).
After a median follow-up of 22 (IQR 15–27) months, 
18 patients were alive; 2 had died of causes considered un-
related to TB. Sputum cultures had converted for 19 pa-
tients, 4 of whom had completed treatment and a median of 
38 (IQR 29–40) months of posttreatment follow-up. Medi-
an time from treatment initiation to culture conversion was 
100 (IQR 75–114) days. One patient is still under treatment 
and has not experienced culture conversion. No patients 
were lost to follow-up.
Conclusions
This small series of XDR TB cases managed in a high-
income country illustrates the potential safety and effi-
cacy of multidisciplinary and individualized treatment 
with a multidrug regimen that includes new anti-TB 
agents (e.g., bedaquiline); innovative use of older agents 
(e.g., linezolid); and the combination of imipenem plus 
amoxicillin/clavulanate. The series also emphasizes dif-
ficulties faced by healthcare professionals caring for 
XDR TB patients.
The final outcome could not be ascertained for most 
study patients because they are still receiving antimyco-
bacterial therapy; however, the 90% survival rate after a 
median follow-up of 22 months after treatment initiation 
is reassuring and compares favorably with survival rates 
of 66%, 54%, and 38% in the United States (4), South 
Africa (5), and the United Kingdom (6), respectively. The 
high rate of microbiologic conversion in our study (95%) 
also reflects the potentially achievable treatment efficacy, 
even in the context of previously treated XDR TB cases.
Our findings should be interpreted cautiously be-
cause of the small number of patients and the relatively 
short follow-up at the time of this writing. However, the 
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Table 1.	Clinical	and	demographic	characteristics	of	20	persons	with	extensively	drug-resistant	TB,	France,	2009–2014* 
Characteristic Value† 
Age,	y	(range) 37.1	(32–40.1) 
Sex,	no.	patients  
 M 18 
 F 2 
Country	of	origin,	no.	patients  
 Georgia 17 
 Armenia 2 
 Russian Federation 1 
Body	mass	index,	kg/m2 (range) 19.8	(17.7–22.7) 
Past	imprisonment,	no.	patients/no.	total	(%) 4/18	(22.2) 
Past or present intravenous drug use, no. patients/no.	total	(%) 10/20	(50) 
Previous	history	of	TB,	no.	patients/no.	total	(%) 19/20	(95) 
Previous anti-TB	treatment,	no.	patients/no.	total	(%) 19/20	(95) 
Previous	thoracic	surgery	for	TB,	no.	patients/no.	total	(%) 3/20	(15) 
HIV	infection,	no.	patients/no.	total	(%) 2/20	(10) 
Hepatitis	C	virus	infection,	no.	patients/no.	total	(%) 12/20	(60) 
Duration	of	TB	symptoms	before	current	admission,	y	(range) 2.4	(0.5–7) 
Organs involved, no. patients  
 Lungs 20 
 Epididymis 1 
Weight loss, no. patients/no.	total	(%)‡ 15/17	(88.2) 
Prolonged	fever,	no.	patients/no.	total	(%)§ 8/16	(50) 
Hemoptysis,	no.	patients/no.	total	(%) 13/16	(81) 
Serum	albumin,	g/L	(range) 30	(26.5–32.7) 
Cavitary lesions	on	chest	radiographs	or	CT	scan	images,	no.	patients/no.	total	(%) 19/19	(100) 
Multilobar	radiological	involvement,	no.	patients/no.	total	(%) 18/19	(94.7) 
*CT,	computed	tomography;	TB,	tuberculosis. 
†Quantitative data are median (interquartile range);	qualitative	data	are	no.	patients/no.	with	data	available (%). 
‡Loss	of	>5%	of	total	bodyweight. 
§Body temperature >38C	during	at	least	3	weeks. 
 
DISPATCHES
overall figures of culture conversion are more satisfactory 
than those previously reported in high-income countries, 
where conversion rates ranged from 46.7% to 76.1% 
(4,6–10), and in high-prevalence settings, where conver-
sion rates are lower (5,11,12). Preliminary results from 
a study conducted in South Africa were more favorable: 
samples from 48 (76%) of 63 patients with 6 months fol-
low-up were culture-negative (13). Postsurgery sputum 
conversion was rapidly achieved for patients in our study; 
thus, pulmonary resection surgery, although risky, may 
also have contributed substantially to treatment successes.
Numerous difficulties were encountered during the 
study. Patients were referred to our centers soon after ar-
riving in France, causing communication difficulties for 
patients with a limited understanding of French and Eng-
lish. Medical histories were long and complex, and most 
patients were in advanced stages of pulmonary TB.
The numerous side effects observed during prolonged 
anti-TB regimens must be optimally and intensively man-
aged; otherwise, patients may not complete treatment. Be-
cause of the limited number of potentially active anti-TB 
agents, drugs with documented long-term toxicities must also 
be included in multidrug regimens. The high incidence of 
breakthrough candidemia cases (5/20 patients [25%]) was not 
anticipated, although prolonged exposure to broad-spectrum 
antimicrobial drugs and long-term central venous access are 
acknowledged risk factors for candidemia. This risk must be 
taken into account when considering treatment of XDR TB 
with carbapenems and amoxicillin/clavulanate. The overall 
good tolerability of linezolid may be a result of the low dos-
age (routinely, 600 mg/d initially, decreased to 300 mg/d if 
toxicity is suspected, even with limited evidence).
Financial, social, and cultural aspects of the man-
agement of vulnerable and marginalized patients are also 
essential and time-consuming. Prolonged hospital stays 
were necessary for patients in our study, resulting in high 
healthcare costs, as previously reported in South Africa 
(14). Limited resources and vulnerability are risk factors 
for noncompliance and disease progression. However, fail-
ure to adequately address these issues would translate into 
additional XDR TB transmission in the community and 
increased illness and death, which could result in a much 
higher societal burden. Previous experience in high-income 
countries has documented that comprehensive care of TB 
patients is cost-effective, even in the most vulnerable and 
marginalized populations, especially when multidrug-re-
sistant or XDR TB are involved (15).
Our results reflect the situation in a high-income set-
ting with free access to all potentially active drugs, exten-
sive investigation of responsible strains (e.g., using DST 
and genotypic tests), daily monitoring of adverse events, 
regular multidisciplinary meetings to tailor treatment to 
any new event and evaluate the need for thoracic surgery 
in selected cases, dedicated medical and paramedical 
staff, and psychosocial support. Unfortunately, the situ-
ation may not be the same in the countries most affected 
by XDR TB.
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Table 2. Anti-TB	agents	used	in	the	treatment	of	persons	with	extensively	drug-resistant	TB,	France,	2009–2014* 
Drug 
No.	patients	previously	treated	with	
drug/no.	with	available	data	(%)	 
No.	patients	with	resistant	
strains†/no.	with	available	data	(%) 
No.	study	patients	treated	with	
drug/no.	with	available	data	(%) 
Rifampin 12/15	(80) 20/20	(100) 0/20 
Isoniazid 13/15	(86.7) 20/20	(100) 0/20 
Pyrazinamide 14/15	(93.3) 15/17	(88.2) 9/20	(40) 
Ethambutol 13/14	(92.9) 17/20	(85) 5/20	(25) 
Streptomycin 6/14	(42.9) 19/20	(95) 0/20 
Amikacin 3/14	(21.4) 10/20	(50) 12/20	(60) 
Kanamycin 5/14	(35.7) 19/20	(95) 0/21 
Capreomycin 9/15	(60) 16/20	(80) 2/20	(10) 
Ofloxacin 4/14	(28.6) 20/20	(100) 0/20 
Levofloxacin 3/12	(25) NA NA 
Moxifloxacin 4/14	(28.6) 14/19	(73.7) 7/20	(35) 
Ethionamide 9/15	(60) 17/20	(85) 5/20	(25) 
Linezolid 0/14 0/20 20/20	(100) 
p-aminosalicylate 14/17	(82.4) 4/20	(20) 16/20	(80) 
Amoxicillin/clavulanate 3/14	(21.4) NA 19/20	(95) 
Imipenem 0/14 NA 19/20	(95) 
Cycloserine 12/15	(80) 16/21	(76.2) 13/20	(65) 
Clarithromycin 2/13	(15.4) NA 0/21 
Clofazimine 2/13	(15.4) NA 9/18	(50) 
Bedaquiline 0/20 NA 16/20	(80) 
*N/A,	no	available	data;	TB,	tuberculosis. 
†Determined by in vitro susceptibility testing at admission. 
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